Cite
Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
MLA
Volterrani, Maurizio, et al. “Therapeutic Options of Angiotensin Receptor Neprilysin Inhibitors (ARNis) in Chronic Heart Failure with Reduced Ejection Fraction: Beyond RAAS and Sympathetic Nervous System Inhibition.” International Journal of Cardiology, vol. 226, Jan. 2017, pp. 132–35. EBSCOhost, https://doi.org/10.1016/j.ijcard.2016.04.180.
APA
Volterrani, M., Iellamo, F., Senni, M., & Piepoli, M. F. (2017). Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. International Journal of Cardiology, 226, 132–135. https://doi.org/10.1016/j.ijcard.2016.04.180
Chicago
Volterrani, Maurizio, Ferdinando Iellamo, Michele Senni, and Massimo F. Piepoli. 2017. “Therapeutic Options of Angiotensin Receptor Neprilysin Inhibitors (ARNis) in Chronic Heart Failure with Reduced Ejection Fraction: Beyond RAAS and Sympathetic Nervous System Inhibition.” International Journal of Cardiology 226 (January): 132–35. doi:10.1016/j.ijcard.2016.04.180.